Tae Yang 3C Co., Ltd. (XKON:052960)
South Korea · Delayed Price · Currency is KRW 3,295.00
+5.00 (0.15%)
At close: Oct 23, 2026
Tae Yang 3C Revenue
In the year 2021, Tae Yang 3C had annual revenue of 60.00B KRW with 11.96% growth. That makes Tae Yang 3C the 28,639th largest company in the world by revenue and 1,759th in South Korea.
Revenue
60.00B
Revenue Growth
+11.96%
P/S Ratio
0.27
Revenue / Employee
153.07M
Employees
392
Market Cap
16.10B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 60.00B | 6.41B | 11.96% |
| Dec 31, 2020 | 53.59B | -14.32B | -21.09% |
| Dec 31, 2019 | 67.91B | -160.56M | -0.24% |
| Dec 31, 2018 | 68.08B | -2.46B | -3.49% |
| Dec 31, 2017 | 70.53B | 4.17B | 6.28% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Kwangdong Healthbio | 38.10B |
| Ihsung Cni | 21.92B |
| Kostek Systems | 19.82B |
| JMMULTI | 18.41B |
| EB Tech | 3.88B |
| SR biotek | 1.62B |
| Moogene Medi | 12.95M |